Observational studyJournal of hepatology2020
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.
Observational study in Journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 235 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis - a Multicentre, Prospective, Observational Study From the SingHealth Chronic Liver Disease Registry (SoLiDaRity-DAM)
Who cites it
235 citing papers in PubMed, 3 syntheses or guidelines pooled it, 483 citations in OpenAlex.
- Albumin for people with liver cirrhosis and bacterial infections.The Cochrane database of systematic reviews · 2026Pooled it
- [Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Guideline
- Systematic review and meta-analysis of biomarkers predicting decompensation in patients with compensated cirrhosis.BMJ open gastroenterology · 2024Pooled it
- Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial.Digestive diseases and sciences · 2026Trial
- Baseline Severity and Inflammation Would Influence the Effect of Simvastatin on Clinical Outcomes in Cirrhosis Patients.Digestive diseases and sciences · 2023Trial
- Trial
- Nutritional-inflammatory indices optimize the diagnostic performance of FIB-4 for advanced fibrosis/cirrhosis in patients with benign liver disease.Annals of medicine · 2026Article
- Machine learning-derived clinical phenotypes of ascites in cirrhosis: A multi-center latent class analysis with external validation.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Article
- Dynamic course and outcomes of acute-on-chronic liver failure in the intensive care unit : Insights from a real-world cohort.Wiener klinische Wochenschrift · 2026Article
- Changes in Muscle Mass and the Risk of Liver-Related Events: A Prospective Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Beyond Biochemical Clearance: Linking Immunosuppressive Bile-Acid Removal to Host Defense and Clinical Outcomes in Severe Liver Failure.Critical care explorations · 2026Article
- Plasma Metabolites for Identifying Bacterial Infection in Acute-on-chronic Liver Failure: A Prospective Multicenter Study.Journal of clinical and translational hepatology · 2026Article
- HBV re-activation is associated with increased mortality and dysregulation of oxidative and polyamine metabolism in pre-acute-on-chronic liver failure.Cell communication and signaling : CCS · 2026Article
- A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper.Hepatology international · 2026Article
- Prognosis of pediatric hepatic Wilson disease with ATP7B loss of function variants.Clinical and experimental pediatrics · 2026Article
- Endoscopic variceal ligation-induced ulcer bleeding: incidence by indication, real-world treatment, and outcomes.BMC gastroenterology · 2026Article
- Acute-on-Chronic Liver Failure: An Eroded Cliff Hit by a Storm-A Narrative Review.International journal of molecular sciences · 2026Review
- Correspondence to editorial on "Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation".Clinical and molecular hepatology · 2026Article
- mRNA vaccines for hepatocellular carcinoma: mechanisms, therapeutic strategies, and clinical perspectives.Hepatology international · 2026Review
- Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors.Alimentary pharmacology & therapeutics · 2026Article
175 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
71 authors at 20 institutions in 14 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsAcute decompensation (AD) of cirrhosis is defined as the acute development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof, requiring hospitalization. The presence of organ failure(s) in patients with AD defines acute-on-chronic liver failure (ACLF). The PREDICT study is a European, prospective, observational study, designed to characterize the clinical course of AD and to identify predictors of ACLF.
methodsA total of 1,071 patients with AD were enrolled. We collected detailed pre-specified information on the 3-month period prior to enrollment, and clinical and laboratory data at enrollment. Patients were then closely followed up for 3 months. Outcomes (liver transplantation and death) at 1 year were also recorded.
resultsThree groups of patients were identified. Pre-ACLF patients (n = 218) developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively. Unstable decompensated cirrhosis (UDC) patients (n = 233) required ≥1 readmission but did not develop ACLF and had mortality rates of 21.0% and 35.6%, respectively. Stable decompensated cirrhosis (SDC) patients (n = 620) were not readmitted, did not develop ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups differed significantly regarding the grade and course of systemic inflammation (high-grade at enrollment with aggravation during follow-up in pre-ACLF; low-grade at enrollment with subsequent steady-course in UDC; and low-grade at enrollment with subsequent improvement in SDC) and the prevalence of surrogates of severe portal hypertension throughout the study (high in UDC vs. low in pre-ACLF and SDC).
conclusionsAcute decompensation without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. Predicting the development of ACLF remains a major future challenge. CLINICALTRIALS. GOV NUMBER: NCT03056612. LAY SUMMARY: Herein, we describe, for the first time, 3 different clinical courses of acute decompensation (AD) of cirrhosis after hospital admission. The first clinical course includes patients who develop acute-on-chronic liver failure (ACLF) and have a high short-term risk of death - termed pre-ACLF. The second clinical course (unstable decompensated cirrhosis) includes patients requiring frequent hospitalizations unrelated to ACLF and is associated with a lower mortality risk than pre-ACLF. Finally, the third clinical course (stable decompensated cirrhosis), includes two-thirds of all patients admitted to hospital with AD - patients in this group rarely require hospital admission and have a much lower 1-year mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.